Summary
Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.
This is a preview of subscription content, log in via an institution to check access.
References
Lassau N, Chami L, Benatsou B, Peronneau P, Roche A (2007) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 17(6):89–98. doi:10.1007/s10406-007-0233-6
Baeksgaard L, Sørensen JB (2003) Acute tumor lysis syndrome in solid tumors–a case report and review of the literature. Cancer Chemother Pharmacol 51(3):187–192
Teo WY, Loh TF, Tan AM (2007) Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. Ann Acad Med Singapore 36(8):679–683, Review
Lin CJ, Chen HH, Hsieh RK, Chen YC, Wu CJ (2009) Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med Oncol 26(1):93–95. doi:10.1007/s12032-008-9064-0
Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P, Masát P, Nagy K, Galántai I, Kiss C (2007) Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma. Pathol Oncol Res 13(1):57–62. doi:10.1007/BF02893442
Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884–896, Review. doi:10.1200/JCO.2006.06.3602
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044
Nicholaou T, Wong R, Davis ID (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369(9577):1923–1924. doi:10.1016/S0140-6736(07)60903-9
Saylor PJ, Reid TR (2007) Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 25(23):3544–3546. doi:10.1200/JCO.2007.12.0790
Acknowledgement
The authors thank Lorna Saint Ange for editing.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michels, J., Lassau, N., Gross-Goupil, M. et al. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs 28, 690–693 (2010). https://doi.org/10.1007/s10637-009-9275-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9275-z